首页> 外国专利> Major routes (or human methods and alpha_alpha___) in salts using this combination of beta____or producer and alpha__ lambda__a minerals and TNF activity are used. Lambda - epsilon

Major routes (or human methods and alpha_alpha___) in salts using this combination of beta____or producer and alpha__ lambda__a minerals and TNF activity are used. Lambda - epsilon

机译:盐的主要途径(或人为方法和α_alpha___)是使用β-生产者和α_lambda_a矿物质和TNF活性的这种组合来使用的。 Lambda-epsilon

摘要

Here we reveal a derivative that shows the use of ketone and formula (I) or one or more salts and TNF alpha inhibitors Combination of pharmaceutical compositions and ketones containing the derivatives or salts with one or more TNF inhibitors.The composition and the composition are used for treating or preventing autoimmune diseases.In the formula, R1 is an optional___________phenyl heterocyclic group, a group or a group of___phenyl heterocyclic groups, and a group or a group of____ It may be a protection and alkyl group, which is a group of kappa R2.Or an optional protective group of PI alpha a.R3 or R4 PI alpha a._masquerades as an optional group of_ Or PI, alpha, P, and R5.
机译:在此我们揭示了一种衍生物,该衍生物显示了使用酮和式(I)或一种或多种盐和TNFα抑制剂的用途药物组合物和含有该衍生物或盐的酮与一种或多种TNF抑制剂的组合。式中,R 1为任选的___________苯基杂环基,__苯基苯基的基团或基团,以及____的基团或基团,可以为保护基和烷基,其为κR 2的基团。或PI alpha a.R3或R4的可选保护基PIαa._masquerades作为PI或alpha,P,R和R5的可选基团。

著录项

  • 公开/公告号CY1115641T1

    专利类型

  • 公开/公告日2017-01-04

    原文格式PDF

  • 申请/专利权人 TOYAMA CHEMICAL CO. LTD.;

    申请/专利号CY20141100825T

  • 发明设计人 AIKAWA YUKIHIKO;SHIOZAWA SHUNICHI;

    申请日2014-10-10

  • 分类号A61K31/12;A61K31/194;A61K31/423;A61K31/5377;A61K39/395;A61K45;A61K45/06;A61P1;A61P1/16;A61P13/12;A61P19/02;A61P29;A61P37/02;A61P37/06;A61P43;C07D261/20;

  • 国家 CY

  • 入库时间 2022-08-21 13:39:35

相似文献

  • 专利
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号